Abstracts tagged "rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)"

Abstract Number: 321 • 2019 ACR/ARP Annual Meeting
Adherence to Weight-Based Dosing Guidelines in Patients Receiving Hydroxychloroquine for Rheumatoid Arthritis and Systemic Lupus Erythematosus
Tara Skorupa¹ and Robert Shmerling ¹, ¹Beth Israel Deaconess Medical Center / Harvard Medical School, Boston, MA
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly prescribed medication for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and other rheumatic diseases. However, HCQ may cause retinal…
Abstract Number: 2409 • 2019 ACR/ARP Annual Meeting
24-hour Activity Profiling in People Living with Arthritis: Habits Matter
Lynne Feehan¹, Linda Li ¹, Na Lu ² and Hui Xie ³, ¹Arthritis Research Canada and University of British Columbia, Vancouver, Canada, Vancouver, BC, Canada, ²Arthritis Research Canada, Vancouver, Canada, Vancouver, BC, Canada, ³Arthritis Research Canada and Simon Fraser University, Vancouver, BC, Canada
Background/Purpose: Current practices promoting change in physical activity classify individuals as being more or less active. However, across 24-hours people spend time in different types…
Abstract Number: 106 • 2018 ACR/ARHP Annual Meeting
Highly Elevated Levels of Anti-Mitochondrial Antibodies in Systemic Lupus Erythematosus and Rheumatoid Arthritis
Richard Moore¹ and Christian Lood², ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose: We recently described the phenomenon in systemic lupus erythematosus (SLE) in which mitochondria are extruded into the extracellular space during formation of neutrophil extracellular…
Abstract Number: 737 • 2018 ACR/ARHP Annual Meeting
Atherogenic Index of Plasma in Women with Systemic Lupus Erythematosus and Rheumatoid Arthritis: A 10-Year Potential Predictor of Cardiovascular Disease
Nevin Hammam^1,2 and Tamer A Gheita³, ¹University of Alberta, Edmonton, AB, Canada, ²Rheumatology and Rehabilitation Department, Assiut University, Assiut, Egypt, ³Rheumatology Department Faculty of Medicine, Cairo University, Cairo, Egypt
Background/Purpose: Patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are characterized by an increased frequency of cardiovascular diseases (CVD). Early diagnosis of these…
Abstract Number: 1860 • 2018 ACR/ARHP Annual Meeting
Development and Validation of a Microrna Panel to Differentiate between Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Control Subjects
Michelle J. Ormseth, Joseph F. Solus, Quanhu Sheng, Fei Ye, Qiong Wu, Yan Guo, Annette M. Oeser, Ryan Allen, Kasey Vickers and C Michael Stein, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: MicroRNAs (miRNAs) are short non-coding RNAs that regulate genes and have utility as disease biomarkers. Use of small RNA (sRNA) sequencing along with unbiased…
Abstract Number: 2179 • 2018 ACR/ARHP Annual Meeting
Poor Rates of Screening for Retinal Toxicity in Patients on Antimalarial Medications: A Population-Based Study
Ksenia Gukova¹, John M. Esdaile², Hamid Tavakoli³ and J. Antonio Avina-Zubieta^1,2, ¹Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada
Background/Purpose: Antimalarial drugs (AM) are commonly used to treat rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). AM can be associated with retinal toxicity that…
Abstract Number: 8L • 2017 ACR/ARHP Annual Meeting
Prevalence of Blindness in a Cohort of Rheumatologic Patients Treated with Hydroxychloroquine
Dilpreet Singh¹, Leila Muhieddine², Douglas Einstadter³ and Stanley Ballou⁴, ¹Rheumatology, Case Western Reserve University School of Medicine at MetroHealth Medical Center, Cleveland, OH, ²Internal Medicine, Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, ³Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, ⁴Rheumatology, Case Western Reserve University/MetroHealth Medical Center, Cleveland, OH

Background/Purpose: Hydroxychloroquine (HCQ) is widely used in the treatment of chronic rheumatic diseases. Its long-standing use has been associated with retinopathy in a daily and…
Abstract Number: 2825 • 2017 ACR/ARHP Annual Meeting
A Possible Environmental Origin for a Proportion of the Genetic Risk of Rheumatoid Arthritis and Systemic Lupus Erythematosus
John B. Harley¹, Xiaoting Chen¹, Mario Pujato², Daniel Miller¹, Avery Maddox¹, Carmy Forney³, Albert Magnusen³, Arthur Lynch¹, Kashish Chetal⁴, Masashi Yukawa⁵, Artem Barski⁶, Nathan Salomonis⁴, Kenneth Kaufman⁷, Leah C. Kottyan⁸ and Matthew Weirauch⁹, ¹Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Center of Autoimmune Genomics and Etiology (CAGE), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ³Center of Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Division of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Divisions of Allergy and Immunology and Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Divisions of Allergy and Immunology and Bioinformatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, ⁸Center for Autoimmune Genomics and Etiology (CAGE), Division of Allergy and Immunology, Cincinnati Children's Hospital, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹Center for Autoimmune Genomics and Etiology (CAGE) and Divisions of Biomedical Informatics and Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Nearly 150 genetic loci are convincingly associated with lupus (SLE) or rheumatoid arthritis (RA) and underlie their incompletely understood mechanisms of pathogenesis. Since 90%…
Abstract Number: 1027 • 2017 ACR/ARHP Annual Meeting
Quantification of Leukocytes’ Secretome to Guide Diagnosis and Treatment Options in Patients with Suspected Chronic Auto-Inflammatory Syndromes
Philippe A. Tessier¹, Marie-Pier Longchamps¹, Nathalie Amiable¹, Nathalie Pagé¹, Laetitia Michou², Louis Bessette², Paul R. Fortin¹, Alexandra Albert², Anne-Laure Chetaille² and Martin Pelletier¹, ¹Infectious Diseases and Immunity Research Division, CHU de Québec-Université Laval Research Center, Québec, QC, Canada, ²Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Québec, QC, Canada
Background/Purpose: Auto-inflammatory syndromes are inherited conditions characterized by recurrent inflammation (fever, abdominal pain, dermatitis, arthritis). Diagnosis and treatments are challenging as detection rate of mutations…
Abstract Number: 1083 • 2017 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patients Achieved Better Quality of Life Than Systemic Lupus Erythematosus Patients at Sustained Remission: The Impact of Disease Diagnosis on Health-Related Quality of Life Outcomes
Virginia Pascual-Ramos¹, Irazú Contreras-Yáñez², Katya Valencia-Quiñones³ and Juanita Romero-Diaz⁴, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁴Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico
Background/Purpose: Patients with Systemic Lupus Erythematous (SLE) and Rheumatoid Arthritis (RA) had profound negative effects on their health-related quality of life (HRQoL) that can be…
Abstract Number: 1086 • 2017 ACR/ARHP Annual Meeting
Screening and Intervention of Depression in Rheumatoid Arthritis and Systemic Lupus Erythematosus
Rui Zhang¹, Priya Prakash², Amy Wasserman³, Kirk Sperber⁴ and Julia Ash⁵, ¹Medicine -Rheumatology, New York Medical College / Westchester Medical Center, valhalla, NY, ²Rheumatology, NYMC /WMC, VALHALLA, NY, ³Medicine - Rheumatology, New York Medical College / Westchester Medical Center, VALHALLA, NY, ⁴New York Medical College / Westchester Medical Center, Valhalla, NY, ⁵Medicine -Rheumatology, New York Medical College / Westchester Medical Center, Valhalla, NY
Background/Purpose: Depression is common and associated with worse outcomes among patients with RA and SLE. Our study assessed depression using Patient Help Questionnaire (PHQ-9) and…
Abstract Number: 1261 • 2017 ACR/ARHP Annual Meeting
The Effects of Disease Burden, Helplessness, and Pain on Depressive Symptoms in Rheumatoid Arthritis and Systemic Lupus Erythematosus
Sera Ramadan¹, Perry M. Nicassio², George Karpouzas³ and Sarah Ormseth⁴, ¹Internal Medicine, Dignity Health St. Mary Medical Center, Long Beach, CA, ²Cousins Center for PNI, UCLA, LA, CA, ³Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ⁴Rheumatology, Harbor-UCLA Medical Center, Torrance, CA
Background/Purpose: This research tested an integrated framework examining patient global assessment of disease activity (PtGA), maladaptive illness beliefs and pain as determinants of mood disturbance…
Abstract Number: 1299 • 2017 ACR/ARHP Annual Meeting
Patient-Reported Disease Activity and Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus and Rheumatoid Arthritis
Nathaniel Harris¹, Amanda M. Eudy² and Megan E. B. Clowse², ¹Duke University School of Medicine, Durham, NC, ²Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, NC
Background/Purpose: Patient-reported measures of disease activity may provide useful adjuncts to physician-reported measures in identifying pregnancies at greater risk for adverse pregnancy outcomes. Little is…
Abstract Number: 2565 • 2017 ACR/ARHP Annual Meeting
Pharmacodynamic Modeling of BTK Occupancy Versus Efficacy in Ra and SLE Models Using the Novel Specific BTK Inhibitor Evobrutinib
Philipp Haselmayer¹, Monsterrat Camps², Lesley Liu-Bujalski³, Federica Morandi⁴, Jared Head⁴, Simone C. Zimmerli⁵, Lisa Bruns⁶, Andrew Bender⁷, Patricia Schroeder⁸ and Roland Grenningloh⁹, ¹CBD, Merck KGaA, Darmstadt, Germany, ²Immunology, Merck Serono S.A., Geneva, Switzerland, ³Medicinal Chemistry, EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁴Biomolecular Pharmacology, EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁵Immunology, EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁶Immunology, Merck KGaA, Darmstadt, Germany, ⁷TIP Immunology, EMD Serono Research and Development Institute, Billerica, MA, ⁸Translational Pharmacology, EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁹EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA
Background/Purpose: Bruton’s tyrosine kinase (BTK) is a clinically-proven target in several hematological indications. Due to its role in mediating the signaling of both B cell…
Abstract Number: 1212 • 2016 ACR/ARHP Annual Meeting
A Combined Large Scale Meta-Analysis Identifies COG6 As a Novel Shared Risk Locus for Rheumatoid Arthritis and Systemic Lupus Erythematosus
Ana Márquez¹, Laura Vidal-Bralo², Luis Rodriguez-Rodriguez³, Miguel Angel González-Gay⁴, Alejandro Balsa⁵, Isidoro Gonzalez-Alvaro⁶, Patricia Carreira⁷, Norberto Ortego Centeno⁸, Maria del Mar Ayala Gutierrez⁹, Francisco José García-Hernández¹⁰, Francisca González Escribano¹¹, José Mario Sabio¹², Carles Tolosa¹³, Ana Suárez¹⁴, Antonio Gonzalez¹⁵, Leonid Padyukov¹⁶, Jane Worthington¹⁷, Timothy J. Vyse^18,19, Marta E. Alarcon Riquelme^20,21 and Javier Martín¹, ¹Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, PTS-Granada, Granada, Spain, ²Instituto Investigacion Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ³Rheumatology Department and Heath Research Institute (IdISSC), Hospital Clinico San Carlos, Madrid, Spain, ⁴Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain, ⁵Department of Rheumatology and Institute for Health Research (IdiPAZ), University Hospital La Paz, Madrid, Spain, ⁶Rheumatology, Rheumatology Service, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ⁷Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁸Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain, ⁹Department of Internal Medicine, Hospital Carlos Haya, Málaga, Spain, ¹⁰Department of Internal Medicine, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ¹¹Department of Immunology, Hospital Universitario Virgen del Rocío (IBiS, CSIC, US), Sevilla, Spain, ¹²Department of Internal Medicine, Hospital Virgen de las Nieves, Granada, Spain, ¹³Department of Internal Medicine, Hospital Parc Taulí, Sabadell, Spain, ¹⁴Department of Functional Biology, Immunology Area, Faculty of Medicine, University of Oviedo, Oviedo, Spain, ¹⁵Laboratorio de Investigación 10 and Rheumatology Unit, Instituto de Investigación Sanitaria - Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ¹⁶Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ¹⁷Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ¹⁸Department of Medical and Molecular Genetics, King's College London, London, United Kingdom, ¹⁹Division of Immunology, Infection and Inflammatory Disease, King’s College London, London, United Kingdom, ²⁰Centro de Genómica e Investigación Oncológica (GENYO), Pfizer-Universidad de Granada-Junta de Andalucía, Granada, Spain, ²¹Institute for Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: One of the main limitations of the association studies in autoimmunity is the difficulty in identifying genetic risk variants with modest effects, given the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].